Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.
The use of protease Inhibitors (PI) has been associated with many adverse effects including increased tendency to bleed, which is particularly problematic in individuals with congenital coagulation disorders. We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). The bleeding resolved on discontinuation of APV. This case report highlights a need for awareness of increased bleeding as a potentially serious complication associated with the use of all currently licensed PIs in individuals with hemophilia.
Kodoth
S
S
Department of Pediatric Allergy and Immunology, Northshore University Hospital, NYU School of Medicine, Manhasset, New York 11030, USA.
Bakshi
S
S
Scimeca
P
P
Black
K
K
Pahwa
S
S
D000328:Adult; D002219:Carbamates; D003937:Diagnosis, Differential; D005169:Factor VIII / Q000627:therapeutic use; D005663:Furans; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000175:diagnosis* / Q000000981:diagnostic imaging; D008297:Male; D013449:Sulfonamides / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D005169:Factor VIII